Evaxion Biotech A/SEVAX
13F holders, Q2 2024 (June 30)6holders
2new positions
2sold out
$2.90avg. 13F price*
At the end of Q2 2024, 6 institutions reported holding Evaxion Biotech A/S (EVAX) in their 13F filings, unchanged from Q1 2024. 2 opened new positions and 2 sold out. The largest holders were Armistice Capital, LLC ($1.1M), Invst, LLC ($156K) and Beacon Capital Management, LLC ($14K).
- Company
- Evaxion Biotech A/S
- CUSIP
- 29970R204
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $156K |
| Exits | 2 | $26K |
All 13F filers, Q1 2024 → Q2 2024: 80,479 shares bought and 8,171 shares sold, net +72,308 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Armistice Capital, LLC | 0.03% | Add +6.8% | 392,000 | $1.1M |
| Invst, LLC | 0.02% | New | 54,000 | $156K |
| Beacon Capital Management, LLC | 0.00% | No change | 4,863 | $14K |
| JPMorgan Chase & Co. | 0.00% | Add +209.2% | 2,180 | $6K |
| Rhumbline Advisers | 0.00% | No change | 290 | $828 |
| SouthState Bank Corp | 0.00% | New | 4 | $12 |
"% of holder's portfolio" is EVAX's weight in each manager's 13F, not the share of Evaxion Biotech A/S the manager owns.